PF-03715455

Request For Quotation
PF-03715455 Suppliers list
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: HANGZHOU CLAP TECHNOLOGY CO.,LTD  
Tel: 86-571-88216897,88216896 13588875226
Email: sales@hzclap.com
Company Name: DC Chemicals  
Tel: 021-58447131 13564518121
Email: doncunbiosci@gmail.com
Company Name: ChemeGen(Shanghai) Biotechnology Co.,Ltd.  
Tel: 18818260767
Email: sales@chemegen.com

PF-03715455 manufacturers

  • PF-03715455
  • PF-03715455 pictures
  • $2.00
  • 2026-08-25
  • CAS:1056164-52-3
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 100kg
PF-03715455 Basic information
Product Name:PF-03715455
Synonyms:PF-03715455;Urea, N-[1-(3-chloro-4-hydroxyphenyl)-3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-[[2-[[3-[2-[(2-hydroxyethyl)thio]phenyl]-1,2,4-triazolo[4,3-a]pyridin-6-yl]thio]phenyl]methyl]-;PF03715455,PF 03715455;1-(3-(tert-Butyl)-1-(3-chloro-4-hydroxyphenyl)-1H-pyrazol-5-yl)-3-(2-((3-(2-((2-hydroxyethyl)thio)phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)thio)benzyl)urea
CAS:1056164-52-3
MF:C35H34ClN7O3S2
MW:700.27
EINECS:
Product Categories:
Mol File:1056164-52-3.mol
PF-03715455 Structure
PF-03715455 Chemical Properties
Melting point 220 °C
density 1.39±0.1 g/cm3(Predicted)
pka7.45±0.20(Predicted)
Safety Information
MSDS Information
PF-03715455 Usage And Synthesis
UsesPF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease)[1][2].
in vivo

PF-03715455 treatment shows that the Vss and T1/2 are 0.19 L/kg, 1 hour, respectively[2].

Animal Model:Male CD Sprague Dawley rats (300-450 g)[2]
Dosage:1 mg/kg
Administration:I.v. (Pharmacokinetic Analysis)
Result:The Vss, and T1/2 were 0.19 L/kg, 1 hour, respectively.
IC 50p38α: 0.88 nM (IC50); p38β: 23 nM (IC50)
References[1] Norman P, et al. Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92. DOI:10.1517/13543784.2015.1006358
[2] Millan DS, et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem. 2011 Nov 24;54(22):7797-814. DOI:10.1021/jm200677b
PF-03715455 Preparation Products And Raw materials
Tag:PF-03715455(1056164-52-3) Related Product Information
2-Propenoic acid, 3-[2,6-dichloro-4-[[[4-[3-(2,2-dimethyl-1-propoxypropyl)-2-methoxyphenyl]-2-thiazolyl]amino]carbonyl]phenyl]-2-methyl-, (2E)- gamma-Glu-Cys trifluoroacetate salt SB 203580 Doramapimod TRi-1 Immunology/Inflammation Compound Library